Probabilistic Autoencoder for Chemical Compound Structure Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for exploring lead compounds are slow, costly, and inefficient, often failing to identify compounds with desired properties and leading to toxicity issues, and lack effective prediction of off-target interactions.
Innovation Solution
A computer system utilizing a probabilistic autoencoder and generative models to directly generate chemical compound representations, predicting properties such as bioassay results, toxicity, and solubility, while minimizing reconstruction and regularization errors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high throughput screening or virtual screening methods are used to explore lead compounds, then compound candidates can be identified, but the process becomes slow, costly, and computationally intensive
Solution Approach 1:
The system performs preliminary action by pre-training the generative model on extensive chemical compound data to learn structural patterns and property relationships before actual lead compound exploration. This pre-learning phase enables the model to rapidly generate promising candidates without requiring time-consuming iterative screening during the actual drug discovery process
Solution Approach 2:
The patent replaces traditional mechanical screening systems (high throughput physical screening or conventional virtual screening algorithms) with an intelligent generative model based on deep learning. This substitution transitions from exhaustive search mechanisms to pattern recognition and generation, dramatically reducing computational time and resource requirements while maintaining or improving compound identification accuracy
2Reliability
If exhaustive screening from vast lists of chemical compound candidates is performed, then more candidates are evaluated, but costs and computational resources increase significantly
Solution Approach 1:
The generative model applies local quality by focusing computational resources on generating and evaluating specific regions of chemical space that are most likely to contain lead compounds with desired properties. Rather than uniformly screening all possible compounds, the model learns to concentrate exploration on chemically relevant and biologically active regions, reducing overall computational energy consumption while maintaining high hit identification rates
Solution Approach 2:
The system changes parameters by transforming the screening approach from evaluating existing compound lists to generating novel compound structures with optimized properties. The generative model adjusts molecular parameters (structural features, functional groups, stereochemistry) to directly produce candidates with target properties, eliminating the need for exhaustive evaluation of vast compound libraries and significantly reducing computational energy requirements
3Manufacturing precision
If current screening methods successfully find lead compounds, then compounds with desired properties are identified, but toxicity and side effects are often not revealed until later clinical trials
Solution Approach 1:
The system performs preliminary safety assessment by integrating toxicity prediction capabilities into the compound generation process itself. The generative model is trained to simultaneously optimize for desired therapeutic properties and minimize toxicological risks, performing safety evaluation before compounds reach clinical trials. This preliminary action identifies and filters out potentially toxic compounds early in the design phase, preventing later failures in clinical development
Solution Approach 2:
The patent implements feedback mechanisms by incorporating multiple property predictions (including toxicity metrics) back into the generative model during compound design. The model receives feedback on predicted toxicological properties and adjusts generated structures to reduce harmful effects while maintaining therapeutic activity. This continuous feedback loop enables real-time optimization of safety profiles alongside efficacy, significantly reducing the risk of toxicity-related failures in later clinical trials
4Adaptability or versatility
If traditional drug design methods are used, then existing compound libraries are screened, but the ability to directly generate compounds with desired properties is limited
Solution Approach 1:
The patent applies inversion by reversing the traditional drug design workflow. Instead of starting with existing compounds and screening them for desired properties, the system inverts the process by first specifying target properties and then generating compounds that inherently possess those properties. The generative model works backward from desired outcomes (therapeutic efficacy, safety profile, pharmacokinetic properties) to create optimized molecular structures, dramatically improving both the flexibility to achieve specific property targets and the efficiency of the overall drug discovery process
Data Source
AI summary
A computer system includes one or more memories and one or more processors configured to cause a generative model to generate structural information regarding a chemical compound by inputting a latent representation into the generative model, wherein the generative model has been trained such that differences between structural information regarding other chemical compounds and reconstructions of the structural information regarding the other chemical compounds generated by the generative model are reduced, the reconstructions being generated by inputting latent representations into the generative model, the latent representations being generated based on the structural information regarding the other chemical compounds.